text:
UPDATED Sep. 15, 2022, at 2:00 PM
All The Science You Need To Make Your COVID-19 Decisions
We're tracking the research so you don't have to.
By Maggie Koerth
UPDATE (SEPT. 15, 2022, 2:00 P.M.): When we started this project, Americans were still deciding how to live with COVID-19. Nearly three years since the virus was discovered, we think most people have figured out their risk tolerances. So, with changes to protocols and information about COVID-19 coming more slowly, we are pressing pause on this project. We are no longer updating it with new guidance or science.
If there's one thing we've learned since March 2020, it's that pandemics are all about hard decisions. It's hard to keep track of the information that helps us make those choices — let alone notice or remember when new science and expert recommendations come along. At FiveThirtyEight, we want to help. We've read the science and have come up with broad assumptions you can make based on where the evidence is. When the science changes, so will the assumptions: We'll be updating this page regularly as new research is published.
We think these assumptions will help you more easily make decisions for yourself and your family. (But do let us know if there are risk-assessment questions you think we're leaving out.) We want this tool to be something that helps take the stress out of decision-making so that you can worry more about the best way to live and less about the virus.
What We're Tracking:
What We're Tracking
📁Should I get a booster?
📁Should I vaccinate my kid?
📁What test should I take?
📁How long should I quarantine?
📁How effective are masks?
📁Will I spread COVID-19?
📁How much should I worry about long COVID?
📁Should Omicron change my approach?
📁Can I catch COVID-19 outside?
📁Booster
📁Kids
📁Testing
📁Quarantine
📁Masks
📁Spreading
📁Long COVID
📁Variants
📁Outside transmission
Should I get the omicron-specific (or "bivalent") booster shot?
LAST UPDATED SEPT. 15, 2022, AT 2:00 P.M.
What you can assume
If you are planning to get a booster after Sept. 1, 2022, you will receive the omicron-specific version. When the FDA authorized the new booster on Aug. 31, it removed authorization to use older, monovalent booster vaccines for people 12 and older. It may take a while for facilities everywhere to have the omicron boosters. But, generally speaking, this is what a booster shot is now. (The omicron-specific vaccine cannot be used for a primary vaccination, so those are still original vaccines.) This will likely expand to younger age groups over the course of fall 2022.
As for whether you should get a booster at all, and when: That's a question that the CDC and independent medical experts have shown some divergence on. Most people are eligible to get an omicron booster if it has been two months since your last COVID shot (either a primary vaccination or a booster), and CDC officials encourage anyone who is eligible to get it. (Guidelines are different for adults and teens who are immunocompromised.) But outside experts have said that waiting longer than two months between boosters is preferred, and in fact, there might not be much benefit from getting boosters any more frequently than every six months.
Why we make this assumption
Infection with COVID can provide similar levels of immunity as vaccination, just with more risks of side-effects. A combination of vaccination and infection might provide the highest level of immunity.
▹ Read more
Research over the last two years has shown that COVID infections can confer immunity that can be as effective as the immunity conferred by vaccines. Growing evidence continues to show that a combination of infection and vaccination is probably the most effective at preventing future infections (though there is no omicron-specific information on this yet). But it's not really clear whether that means infections from omicron will end the pandemic by making enough people immune to future waves. That could happen, but what we do know about natural immunity suggests the future may not be so straightforward. For instance, mild and asymptomatic COVID infections have long been associated with less effective immunity later. Another potential problem: Omicron might be different enough from other variants that immunity to it might not mean much when new variants come along.
Should I get my child vaccinated?
LAST UPDATED JUNE 21, 2022, AT 2:00 P.M.
The answer depends on age and how you evaluate risk for your family. The benefits are clear for children 12 and over, and even though effectiveness at preventing transmission dropped dramatically for kids between the ages of 5 and 12 during the omicron wave, some evidence suggests that the vaccine still reduces severe side effects from infection for this group.
Children younger than 5 are now also eligible for vaccination, with a choice of Pfizer and Moderna vaccines. But there were questions, even by members of the FDA panel, about how necessary vaccination at this age really was, because the risk of death is so low. That said, the panel voted unanimously to approve vaccine access because they can still prevent infection and severe illness, the risks were extremely low and the members felt this was a decision parents should be able to make with their doctors.
The delta and omicron variants are more contagious and more likely to produce breakthrough cases, even though they don't seem to be worse for kids than for adults, either in likelihood of transmission or severity of illness. The raw number of pediatric hospitalizations for COVID-19 went up during the omicron wave, but that's basically because everyone was more likely to get infected. Kids who spend their time around vaccinated adults and teens are at lower risk, but the potential benefits of vaccinating kids outweigh the risks.
Data from trials of both Pfizer and Moderna show that children under 6 benefit from vaccination. But the data is not super clear-cut, especially when it comes to Pfizer, which is based on a very small trial and requires three doses to reach a useful level of efficacy.
The Pfizer and Moderna vaccines for preschool-age kids are not identical. The Moderna vaccine is approved for children ages 6 months to 5 years and requires two initial doses, each at a quarter of the dosage given to adults. In clinical trials during the omicron wave, it demonstrated an efficacy against infection of 51 percent in children 6 to 23 months of age, and 37 percent in children ages 2 to 5 years. These results came from a study that involved 5,400 children. (The FDA also approved a third booster of Moderna for high-risk kids over 6 months of age to be administered at least one month after the second dose.) The Pfizer vaccine was approved for children ages 6 months to 4 years old. The FDA's approval cites research on the immune response induced by the vaccine — which was comparable to adults — but does not include research of efficacy at preventing COVID infection. That's because the committee deemed this research "not to be reliable." Pfizer had originally been testing a two-dose version of this vaccine, but their efficacy rates were so low — just 15 percent according to FDA follow up data — that Pfizer went back and decided this would be a three-dose vaccine and started trying to test that instead. They lost a lot of trial participants in the process. Most just never got the third shot and couldn't be included in the analysis. Pfizer is touting its vaccine as 80 percent effective. But that was based on a group of just 10 participants — three who got the vaccine and seven who got a placebo. That sample is nowhere near big enough to say anything definitive about efficacy. Scientists already expect the effectiveness of the Pfizer vaccine to end up being about the same as Moderna in the real world, but to get that you have to get all three shots — a regimen onerous enough that it wasn't even followed by most of the participants in the clinical trial.
The benefits of vaccinating kids outweigh the risks for kids ages 12 and over, even after omicron is taken into account. This variant seems to have drastically reduced the efficacy of the lower-dose vaccine administered to kids 11 and younger, at least when it comes to preventing infection. But it's likely this age group is still getting a useful amount of protection against severe illness.
As of early November, the CDC approved vaccination for children ages 5 and up. That was based on results of Pfizer's clinical trial and an analysis of the potential risks. An independent FDA analysis considered both Pfizer's finding that its vaccine is 91 percent effective at preventing COVID in children ages 5 to 11 as well as the risks of both severe illness and a rare (but mild) vaccine side effect that has caused inflammation of heart tissue, particularly in young men. But Pfizer's data included no instances of heart inflammation in the children ages 5 to 11 who received the vaccine, despite it occurring in an estimated 71.5 cases per million 16- and 17-year-old boys vaccinated. Ultimately, the FDA concluded that the benefits of vaccination outweighed the risks. Even if the number of kids hospitalized for heart inflammation were higher than the number of kids hospitalized for COVID, getting vaccinated would still be worth it because being hospitalized for heart inflammation is still that much less risky than being hospitalized for COVID. For example, being infected with COVID can cause a severe reaction called multisystem inflammatory syndrome, and studies suggest that vaccination can be more than 90 percent effective at preventing that in kids 12 and up, even if the kid still gets infected. Unfortunately, that data was all gathered before the omicron wave. This variant turned out to be extremely good at evading all kinds of immunity, and preliminary data published (but not yet peer-reviewed) in February 2022 suggests it rendered the lower-dose vaccine given to young children all but useless against infection. Among more than 365,000 children ages 5 to 11, efficacy rates measured between December of 2021 and January of 2022 fell from 65 percent to just 12 percent. It is less clear how much efficacy the vaccines retained against severe illness, hospitalization and death. Those outcomes are rare enough in young children, generally, that it's hard to get a precise understanding of how much vaccines reduce their likelihood. The preliminary data does suggest, however, that the vaccines did retain more effectiveness in this area than they did in preventing infection, broadly. In fact, in April 2022, England's National Health Service approved the use of the Pfizer vaccine in children ages 5 to 11, even though most children in that country are estimated to have already been infected with COVID — largely on the basis of the vaccine's potential to reduce severe side effects and risk of long COVID. But omicron's ability to escape the lower-dose vaccine immunity does mean that kids 11 and under benefit less from vaccination. Since this news came out, Pfizer has published data intended to support authorizing a third dose for kids 5-11.
The omicron variant is not more dangerous for kids than previous variants, nor more dangerous than it is for adults.
This one is a bit confusing because it is true that pediatric hospitalizations for COVID have risen significantly during the omicron wave. But that is not the same as saying that omicron has made COVID more dangerous for children. If lots and lots more people are catching the virus, more are going to end up in the hospital, even if this variant is overall less likely to produce serious illness. It's a numbers game. Death rates in children remain extremely low — with less than 0.02 percent of COVID cases in children resulting in death. The increased numbers of children in the hospital with COVID also reflect the fact that more kids who happen to have COVID are hospitalized for other things. Hospitals have told news outlets that these kinds of cases might make up the majority of children in hospitals with COVID. Meanwhile, data from the U.K. and South Africa suggest that omicron is not more severe in children, and preliminary data from the United States shows the same trends — including in children under the age of 5, who cannot yet be vaccinated.
Vaccinating those who can be vaccinated protects people who can't.
We know that vaccines work and that vaccinating kids ages 5 to 17 will help protect kids too young to be vaccinated yet. Data from August shows how severe cases of COVID-19 in children became concentrated in the parts of the country with the lowest rates of adult and teen vaccination. In New England, where more than 72 percent of the eligible population was vaccinated, the daily rate of cases of COVID in people 17 and under was about 13 for every 100,000. In the Southeast, where less than 50 percent of eligible people were vaccinated, the daily childhood COVID rate was nearly 50 per 100,000. Between Aug. 14 and Aug. 27, kids under age 18 were more likely to be admitted to the hospital or ER in regions with lower vaccine coverage than in regions with higher vaccination rates. Vaccination reduces the spread of COVID, thereby helping protect those who can't be vaccinated yet.
What test should I take if I've been exposed to COVID-19, and when?
LAST UPDATED AUG. 3, 2022, AT 4:00 P.M.
Rapid at-home tests and PCR tests can both be useful and continue to be effective at identifying cases of omicron-variant illness. PCR tests are becoming harder to get, especially if you are uninsured, though you can get eight free rapid tests through the mail. But it matters when you're using them and what you're trying to do, and omicron should change some of your testing procedures.
If you have symptoms but are still testing negative on a rapid test, scientists say that it's important to test more than once, wear a mask while you are uncertain of your status and consider a PCR test if you have repeatedly tested negative on rapid tests but still suspect you have COVID.
The rapid at-home tests are rated as less sensitive overall.
Sensitivity is defined as the likelihood that a test will spot a potential infection. High-sensitivity tests are unlikely to produce a false negative — that is, send you out into the world thinking you're healthy when you actually have COVID. The tests with the highest sensitivity are molecular (PCR) tests — the sort offered at drive-through clinics and state-run testing centers since early in the pandemic. These rely on specialized laboratory equipment that can find even tiny scraps of viral RNA and then make enough copies of the virus's genetic material so that its presence is detectable. The tests can take several forms, including the ol' swab up the nose, a saliva test or a throat swab. If you're getting the nasal-swab version, the highest sensitivity comes from the tests in which trained health care providers put the swab way up in the back of your nasal cavity. Less intrusive ones work but are more likely to produce a false negative. The at-home kits are antigen tests, which are different (and less sensitive) than molecular tests. The antigen tests are designed to spot relatively large pieces of viral protein — something you're more likely to have if you have a high viral load. Compared with molecular tests, these at-home tests will turn up a false negative more often, especially in asymptomatic people. For example, in a paper that hasn't yet been peer-reviewed, researchers compared PCR and antigen test results at a walk-in testing center in San Francisco. They found that the sensitivity of an antigen test varied a lot, depending on how much virus was present in the person's system; it ranged from 95 percent sensitivity for those with a high viral load, to 65 percent in those with a low viral load. Among the 61 people in the study who had very low viral loads but still tested positive on PCR, none tested positive on an antigen test.
The rapid at-home tests are about as sensitive as PCR tests for the time period when an infected person is most likely to be contagious. And this continues to be true, even as the virus mutates.
Compared with at-home antigen tests, PCR tests are less likely to deliver a false negative over a longer period of time, but when it comes to the critical three days when a COVID-infected person is most contagious, the at-home antigen tests and the PCR tests are both very accurate, according to Michael Mina, a professor of epidemiology at Harvard University. (The U.K. has used antigen tests — which they call "lateral flow tests" — to great effect in stemming the spread of COVID, and a chart in this story can show you the relationship between infectiousness and the effectiveness of both kinds of tests.) Scientists say that this continues to be true, even after months of mutation and all the subvariants of omicron — with some caveats. Both Stephen Kissler, a Harvard public health research fellow, and Dr. Emily Landon, a professor of medicine at the University of Chicago, told us in August 2022 that omicron has not evolved to be less detectable by rapid tests. In fact, according to Kissler, growing levels of immunity — from vaccination and infection — actually mean that infectiousness and symptoms are more likely to align than they were earlier in the pandemic, when people could be infectious for a long period before their bodies began to mount a response to the virus and symptoms emerged. A negative rapid test is still a good indicator that you are unlikely to be contagious. That said, it's important to remember that this status can rapidly change. In the span of a few hours, a person can go from having a low viral load, being noncontagious and testing negative to having a high viral load, being contagious and testing positive, Landon said. It is also possible not to have a high viral load in one part of your body (like your nose) while having a higher load in another part (like your throat). The place where you have the highest load can vary by how you got infected and the variant you got infected with. Finally, people can test ineffectively, getting a negative test result because they didn't swab their nose long or deep enough. For all these reasons, it's really important to test multiple times if you are symptomatic and to test as close as possible to the time of an indoor event to avoid spreading an infection you don't know you have.
If you choose at-home tests, you should test more than once.
Because the sensitivity of the at-home antigen test changes over time, you'll need to test more than once, which is why most kits are sold with two tests in each pack and tell you to test on consecutive days. The tests are most useful if people are doing them regularly over long periods of time — like, say, if school kids or workers were testing daily as part of routine outbreak prevention. The more likely it is that you've been exposed but are getting a negative rapid result, the more you should want to confirm that result. If you're symptomatic and testing negative, you should self-isolate and test for the next two consecutive days. Overall, choosing a test is a matter of balancing accuracy, speed of results and frequency of testing. And there is still a lot we have to learn about the omicron variant that could change testing strategy in the future.
The research on whether antigen tests remain as sensitive to omicron as they were to earlier strains is mixed. It's worth continuing to use them, but you should test multiple times if you are symptomatic and getting a negative result.
Early in the omicron wave, the FDA reported that the most common commercially available antigen tests worked well in laboratory studies and were able to detect the new variant reliably. That is no longer what the agency's site says. Studies done with live virus — as opposed to earlier ones done with heat-inactivated virus — showed that antigen tests may have reduced sensitivity to omicron. That means there might be a higher likelihood of false negatives. Since that announcement was published on the FDA site, other research — both in the laboratory and the real world — has turned up mixed results. Most of this research hasn't yet been peer-reviewed. Some studies, including one done in a lab using live virus, show antigen tests retained their accuracy with omicron. A study from June 2022 that hasn't yet been peer-reviewed found that rapid tests retained a very high sensitivity during the omicron wave. Other studies, including a peer-reviewed laboratory study published in February, found that the tests needed higher amounts of omicron virus to produce a positive result compared with delta. Dr. Emily Landon, a professor of medicine at the University of Chicago, and Stephen Kissler, a research fellow in public health at Harvard, told us in August 2022 that you should still assume that rapid tests are effective at detecting omicron infections. It just means that you should assume they might produce a false negative in the first couple days of an infection, and that you should test repeatedly over several days to get a trustworthy result. This is also why Michael Mina, a Harvard professor of epidemiology who has been arguing for increased use of rapid tests, says that if you are testing before attending an indoor event, you need to be testing immediately before the event. A faster-spreading virus means a virus that is multiplying faster in your body, so your results one or two days before the event might not give you the most accurate understanding of infection status. For best accuracy, test a couple days prior and then test again within a few hours of the event. The Ontario COVID-19 Science Advisory Table has a nice brief that breaks this all down very well.
How long do I have to quarantine if I've been in contact with someone who has COVID-19? And what do I do if I am sick?
The CDC shortened the length of its recommended quarantine on Dec. 27 from 10 days past the point of exposure to five if you are not vaccinated or if you received your primary vaccination a while ago (i.e., more than six months ago for an mRNA vaccine, or more than two months ago for Johnson & Johnson) and have not received your booster. Anyone who has received their booster, whose primary vaccination happened within two or six months (depending on vaccine type) or who has had a documented case of COVID-19 in the last 90 days doesn't need to quarantine after being exposed to an infected person. The agency shortened its recommended self-isolation period for those who test positive as well. They also have a new app on their website to calculate the timing of quarantine, isolation and testing for you, based on a series of questions.
A key point here, though, is that symptom status and strict masking regimens are connected to all these changes. Once you test positive, the CDC is suggesting you leave isolation after five days only if you are asymptomatic at that point — and even then, they want you to wear a mask around everyone until 10 days after exposure. (Check out the section of this dashboard on what we know about how well different kinds of masks work.) Rapid at-home tests should also be an important part of this. That's because CDC guidelines are based on what we know about the average length of time people can spread the virus — you, personally, may be outside that average. The best way to know if you are infectious or not is to take a rapid test.
In fact, Dr. Emily Landon, a professor of medicine at the University of Chicago, said omicron patients are often still infectious at day six or seven. If you are going back into the world after a COVID infection, it's best to wait until you test negative. If you can't do that, it is crucial that you wear a mask around others until you do test negative.
Recommended isolation after a positive test is shorter now, but that doesn't mean we know that you, personally, are infectious for a shorter period of time.
Quarantine means staying home and away from other people after recently being in close contact with someone diagnosed with COVID while you wait to see whether you've been infected. Isolation means staying home and away from other people after you have tested positive for COVID. The CDC now says that everyone, regardless of vaccination status, should isolate for at least five days if they test positive. If at the end of that period you have no symptoms, the CDC says that you can end isolation but that you should continue to wear a mask around others for another five days. This is different than just masking up to go to the grocery store. You should be wearing a mask more extensively during this time than you do when you're sure you're healthy, even if you are vaccinated and boosted. Here's why: Some data suggests people can clear an infection faster than previously assumed, and that the vaccinated return to health faster than the unvaccinated. A study analyzing infections of NBA players, staff and other league affiliates, for example, found vaccinated participants were clearing an infection in 5.5 days on average, and unvaccinated participants in 7.5 days. But there are limitations to this. Omicron-specific data suggests that the variant might result in people being contagious for longer. All studies on this are narrow and may not be something you can extrapolate to everyone, and in any case, they're talking about averages. Your results may not be the same as an average. You should assume that you can still be infectious beyond five days, even if you are vaccinated. This discrepancy between what is average and what is possible is why other countries and the World Health Organization have different (and often stricter) recommendations than the CDC. The WHO, for example, recommends a minimum of 7 days of quarantine, even for people who are up to date on all their shots. Although the shortened CDC isolation and quarantine guidelines initially made no mention of testing as part of the strategy, it now emphasizes it for quarantine, though it's still not part of how the CDC determines when someone can leave isolation. This is partly because we know that PCR tests can produce a positive result long after a person has stopped being infectious. However, rapid antigen tests — the at-home kind from the drugstore — are good at telling you whether you are infectious. (See our section on testing for more information.) If you have COVID, you should use them as a better determinant of when it is safe for you, personally, to leave quarantine and isolation without risk of spreading COVID to friends, family, coworkers and the general public.
Testing and masking are more critical under the new quarantine guidelines.
Quarantine means staying home and away from other people after recently being in close contact with someone diagnosed with COVID while you wait to see whether you've been infected. Isolation means staying home and away from other people after you have tested positive for COVID. The CDC has shortened its quarantine guidelines significantly. People who have received a booster, whose primary mRNA vaccines were less than six months ago or whose primary Johnson & Johnson vaccine was less than two months ago do not have to quarantine — but they should mask for 10 days and be prepared to test and stay home if any symptoms develop. People who are unvaccinated or whose primary vaccinations are outside that range and who haven't gotten a booster should stay home for five days and mask for another five. The CDC also recommends testing at the end of the five days of quarantine, to make sure you aren't infected. If you test positive, you should then enter isolation — and start counting days all over again. This difference in length of quarantine for these two groups is based on data that suggests people who have received their booster shot are significantly less likely to contract the omicron variant than those who have not received a booster or who are unvaccinated. There's also evidence that infectiousness peaks within the first week of a case of COVID. That said, however, there does not seem to be solid omicron-specific data for length of infectiousness. Some preliminary data from Japan suggests it can last longer than for previous variants, and we do know that omicron can evade booster immunity. If you choose to follow these new CDC guidelines and shorten your quarantine, you should be thinking of your mask as important to preventing spread — it should fit better and prevent more particles from escaping than most cloth masks are capable of. Paying attention to symptoms and testing are also a key part of preventing transmission effectively under these guidelines. Michael Mina, an epidemiologist who has extensive experience studying rapid antigen tests, says that for breakthrough infections of omicron in vaccinated people, symptoms seem to be starting before those people become infectious. If you have symptoms, take a test. If the test is negative and you still have symptoms, test on consecutive days because the outcome of a test that is geared to identifying when you are infectious could change.
The new, shorter quarantine and isolation guidelines have a scientific basis — but they also seem to be based on economic and political demands.
Earlier in the fall, Michael Springer, a professor of systems biology at Harvard University, told us that most infected people will show symptoms or a positive test result within 14 days of exposure. But there's a reason quarantine periods aren't 14 days long, he said. Recommended quarantine timelines are based both on scientific evidence about how long it takes for COVID to make a person sick or contagious, and on attempts to balance that with other concerns, like economic constraints, child care availability and plain ol' not wanting to be trapped in the house that long. That's why the WHO includes several different levels of recommendations, depending on economic and public health pressures in the specific country. In December, the CDC received letters from several airlines, including Delta, asking that these isolation times be shortened for breakthrough cases in vaccinated people. The subsequent decision to do so seems to be in response to these letters. Likewise, former CDC Director Tom Frieden described the new guidelines as "taking the world as it is not as we wish it would be." This is not necessarily a bad thing, but experts were very critical of the fact that rapid antigen tests were not initially being heavily recommended or required as a part of the CDC's decision. However, there was also a nationwide shortage of those tests at the time. Now, however, they're easy to find. But while every household can get eight tests free from the government, and some Americans can use HSA and FSA funds to purchase tests, the tests remain expensive. It is important to note that the new CDC guidelines are one way to interpret and make use of data while balancing other factors — but they are not the only way. In countries where rapid tests are not in short supply and are cheap, health care agencies recommend very different quarantine and isolation rules.
If you test positive — and are at high risk of severe illness — there are medications you can take that have been shown to improve outcomes. But you will have to move quickly.
While social media has been full of "treatments" for COVID that don't work (like ivermectin), there are some real medications that do. The bad news is that they're often difficult to get. Monoclonal antibodies — basically just manmade versions of the antibodies your body produces to fight off infection — as well as two kinds of antiviral medications have been approved. Unfortunately, to get the benefits of these medications, you have to start taking them very quickly after diagnosis. A course of antivirals must begin within five days of developing symptoms. In addition, only some people are eligible to take these medications. The government has tried to set up a national system of centers where people can go to be diagnosed and get a prescription for the antiviral drugs at the same time. It's called Test To Treat, and you can use a map to try and find a location near you. However, the system has been heavily criticized (as of April 2022) for not featuring on its official map all the locations that can test and treat, for including places that do not reliably have access to the drugs or charge hefty fees for prescribing them and for leaving large swaths of the country without any nearby centers. Meanwhile, some pharmacies have ended up with too many antivirals while the drugs remain elusive for patients in other places. Test To Treat is a good place to start, but you should understand that it may not make getting the drugs super simple. One other option to consider is fluvoxamine, an antidepressant that has been shown in multiple studies to reduce the risks of hospitalization and serious side effects. This drug does not yet have approval for COVID treatment, but infectious disease experts have begun suggesting it could be used off-label. You'd have to consult your doctor.
Do masks protect you and others from COVID-19?
They do. There's also a growing body of evidence suggesting that mandates — which take a community-wide approach to reducing spread of disease in the community — effectively reduce transmission, hospitalizations and death in communities where they are implemented. Review papers are now also documenting that the bulk of evidence shows a benefit to individual mask wearing as well, even if that benefit is only low-to-moderately effective.
Despite this, mask mandates have been rolled back virtually nationwide, and the CDC has changed its masking guidelines to recommend masking based on local hospitalization rates rather than on local transmission rates. The agency now recommends indoor mask-wearing for everyone only in counties where the risks of hospitalization are high.
Mask effectiveness depends on the kind of mask you use, and you can purchase high-quality masks using HSA and FSA money.) So far, little evidence suggests that masking, specifically, is harming the cognitive or speech development of young children.
Masking reduces the spread of COVID, especially in places where more people are masking, which is why mandates within schools, cities, counties and states matter.
Back in March and April 2020, there was genuine debate among scientists about whether masking was significantly effective at preventing the spread of COVID, especially compared with interventions like social distancing. That has not been the case for well over a year. In January 2021, a systematic review of various types of studies concluded that mask-wearing — especially if widely adopted — was effective at reducing COVID transmission. An September 2021 study of nearly 350,000 adults across 600 villages in Bangladesh found that widespread use of surgical masks, even at levels below 50 percent, reduced the likelihood of contracting COVID by 11 percent — and almost 35 percent for people over 60. And research in the U.S. has shown that masking during surges can help curtail spread and protect populations. Further studies have shown that mandates were effective at reducing COVID in the places they were implemented. For example, when mask mandates were first implemented in some (but not all) Kansas counties in 2020, those counties had COVID rates three times higher than the counties that did not, but within months, that trend had reversed, with the non-mandate counties having rates more than two times higher than those with mandates. Another study found that even in states without mask mandates, county mandates were associated with a nearly 17 percent reduction in COVID cases over the 30 days after implementation. There is also evidence for the effectiveness of mask mandates in schools. A March 2022 study in the journal Pediatrics compared 61 districts across nine states during the fall semester of 2021. The study found that most people were catching COVID outside of school, rather than in it, but that mask mandates in the schools still reduced transmission. For every 100 community-acquired cases, universally masked districts had 7.3 cases of school-transmitted COVID and optionally masked districts had 26.4.
CDC masking guidelines no longer reflect local transmission rates — they are focused more on hospitalizations.
If you are deciding whether to wear a mask indoors based on recommendations made by the CDC, know that the agency's metrics for determining which counties should have universal masking have changed. Risk levels were previously determined by the number of cases in a community, but beginning February 24, 2022, the agency switched to a system that considers a combination of three factors: new COVID-related hospital admissions from the previous week; the percentage of hospital beds currently occupied by COVID patients, and new COVID cases per 100,000 people over the previous week. This change is largely based on the fact that so many people have now either been vaccinated or acquired immunity through infection. Neither vaccine nor infection-mediated immunity is a perfect barrier against getting infected again, but both reduce the risks of severe illness. These guidelines drastically changed the number of counties that were considered high risk and in need of universal masking. Previously, 95 percent of US counties were considered high-risk and had universal masking recommendations. Under the new metrics, that number fell immediately to 37 percent of counties. The new mask guidelines were also extended to schools, with the CDC only recommending universal masking in K-12 schools in those counties with high community-risk levels. This change has been controversial among scientists — some support it, some don't — though not because of the idea that masking may be necessary at some times and unnecessary during others. Instead, the debate largely stems from a question of which metrics should be used to determine low risk and whether the metrics chosen by the CDC truly do enough to protect the most vulnerable, such as immunocompromised people and young children. There's also concern about the way the new guidelines don't seem to factor in the risks posed by long COVID. Earlier in February, for example, a group of public health researchers published an open letter requesting that mask guidance take vaccination rates among children into account.
Masks still work, even if you're the only one using them.
With the elimination of mask mandates from most schools, public buildings and even planes and public transportation, you can no longer rely on community masking to reduce risk in a large, systemic way. The good news is that one-way masking is still useful. Even if you're the only person masked up at the gym or your office or on a flight, you are still protecting yourself more than you would be without a mask. A study from before the pandemic found that average people using an N95 mask can block their exposure to about 80 percent of airborne particles. If you are someone with a high risk of serious COVID side effects, you might want to consider adding a face shield on top of a mask.
There's no evidence that mask-wearing is broadly harming children's development.
Some are worried that very young children may experience developmental delays because the adults around them are wearing masks, potentially preventing them from picking up on facial recognition, emotional cues and speech acquisition. This is not an unreasonable concern to have — researchers have published several papers that express similar concerns — but there isn't much to suggest this is actually happening. That's partly because research has been limited, but also the studies that have been done have found no evidence to support a clear, consistent detrimental impact caused by masking. For example, a study of 7- to 13-year-olds found that kids could successfully infer emotion from masked faces — at about the same rate as they could from faces wearing sunglasses. And a study of interactions between infants and mothers found that while infants reacted to mothers taking masks off and putting them on, wearing a mask did not seem to damage the connection between the two or cause infants distress. Wearing a mask was not analogous to the problems caused when caregivers are emotionally unresponsive or inexpressive. This is not to say, however, that young children aren't experiencing various kinds of delays — just that masking, specifically, does not currently appear to be the cause. Nature published a story in January that got more deeply into evidence of developmental delays and what researchers think is causing them. One study that hasn't yet been peer-reviewed found that babies born during the pandemic were scoring almost two standard deviations lower on a battery of cognitive tests than babies born earlier — and that gross motor skills seemed to be the area most affected. Researchers told Nature that they thought a big factor here was the fact that these children had less access to peers, physical play and interactions with other adults — something caregivers have told scientists they worry about, as well. This theory is backed up by the finding that young children who were in child care or preschool during the pandemic in the U.K. — where face masks have been required in public places until very recently — displayed fewer deficits than those who were not. However, there are some subpopulations (both adults and children) for whom masking does pose speech and communication problems. Numerous studies have found that people who are hard of hearing have significantly more trouble understanding speech and communicating with others because of the way that masking dampens sound and obscures the mouth, and that this can lead to intense feelings of isolation and stress. Some studies found that clear masks can help with this — others found clear masks didn't make a difference.
Your cloth mask is not as effective as you'd like it to be.
Research has shown that not all types of masks are equal. For example, experts have been warning for a while that bandanas and thin fabric neck gaiters aren't effective at blocking transmission of airborne particles. But additional evidence now shows that even multilayered cloth masks aren't as effective as well-fitting surgical or N95 masks. One study that hasn't yet been peer-reviewed found that fabric face masks (which have a lot of variability in design and material) blocked between 62.6 to 87.1 percent of fine particles, while surgical masks blocked an average of 78.2 percent and N95s blocked 99.6 percent. Some countries, including France, have banned DIY cloth masks and stipulated that only certain types of factory-produced varieties are acceptable. Early in the pandemic, cloth masks were promoted as a way to get people masked up during a shortage of higher-quality masks, but mask supply has since caught up with the demand in the United States. N95s — and the Chinese- and Korean-made equivalent KN95s and KF94s — are widely available now, and, as of Sept. 10, the CDC says they should not just be reserved for medical staff. Proper fit is a big deal here, though. A poorly fitting surgical mask is not an upgrade from a well-fitting cloth mask.
You can get multiple reuses out of N95 and KN95 masks.
Remember that these masks were, prior to COVID-19, industrial tools with regulations and recommendations geared toward those uses. They were intended to be thrown away after a single medical procedure or factory shift, so the idea got down to the public that we should also throw these masks away after a few hours or a day of use. But that is not true. In fact, health care workers have reused these masks successfully in the past. The main issue is whether the mask will still fit to your face effectively after multiple uses. There's not a ton of evidence on the fine details of mask reuse, but studies have shown that you can get at least two or three reuses with little change to fit. Outside formal scientific papers, people like Aaron Collins, an aerosol engineer, have been conducting tests of masks for the way people use them now. He's found that, depending on the brand, these masks can maintain high levels of filtration quality through 30-40 hours of light, everyday use.
How likely am I to contract and spread COVID-19 if I'm vaccinated?
LAST UPDATED APRIL 27, 2022, AT 1:00 P.M.
Breakthrough cases have become common since omicron became the dominant variant. The likelihood of an individual contracting COVID-19 depends on a combination of primary vaccination status, booster status, masking, other preventative behavior and how common cases are in your community. Vaccinated people can spread the omicron variant more easily than past variants, and studies suggest you're probably more infectious before symptoms kick in than after.
Vaccinated people are still less likely to catch COVID, especially if they have been boosted.
You can't spread the virus if you don't contract it. And the good news is that vaccination does still protect you against infection. Data from the U.K. found that vaccine effectiveness against omicron fell even further, depending on how long it had been since the person was vaccinated with the Pfizer vaccine. Effectiveness fell to less than 9 percent in people who had been vaccinated 25 weeks ago or longer. That study showed that a booster shot could bring effectiveness back to about 67 percent, though it did decline again to about 46 percent by 10 weeks post-booster. Some people might be more likely to have a breakthrough infection than others. In a recent study that has not yet been peer-reviewed, for example, pregnancy almost doubled the likelihood of a breakthrough infection.
It is much easier for vaccinated people to spread omicron than previous variants.
A U.K. study that has not yet been peer-reviewed found that a booster does reduce the likelihood of spreading omicron — because it prevented people from catching the virus — but boosted people who did get omicron were more likely to spread it than boosted people who got delta. Omicron has definitely changed the calculus here, probably by making it just more likely for vaccinated people to get infected at all.
There are specific complications that put people at higher risk of severe side effects if you spread COVID9 to them — and those complications are common.
Vaccinated people can spread COVID to both vaccinated and unvaccinated people, so it is worth considering the risks others might face if you spread the virus to them. (We address long COVID and other long-term complications in another part of this dashboard.) These higher-risk groups are a combination of two things: direct risks (you have a physical condition that makes severe COVID more likely) and statistical risks (people who have been statistically more likely to die, which is probably less about their group identity and more about how society treats that group and the access they have to health care). The omicron variant produces less severe health outcomes, but because it is also easier to transmit and more people have acquired it, it's also associated with increases in hospitalizations. Being unvaccinated remains a big predictor of severe outcomes, even during and after the omicron wave. For example, during the omicron wave, the hospitalization rate among vaccinated adults peaked at about 23 per 100,000. That same week, the hospitalization rate among the unvaccinated was 150 per 100,000. Age remains the biggest risk factor, with more than 81 percent of COVID deaths happening in people over the age of 65. There is also a long list of conditions that have strong evidence suggesting they increase the risk of severe COVID outcomes. These include cancer, diabetes, pregnancy, chronic kidney disease and a history of smoking. There are also still racial disparities in severity of COVID illness, even after disparities in vaccination rates have narrowed (and in the case of Hispanic Americans, reversed). Scientists think these statistical risk correlations are likely tied to factors like health care access and social stigma, which have led to minority communities experiencing increased rates of some of the chronic diseases that put people at higher risk for complications after contracting COVID. The important takeaway here is that it's not rare for people to be over the age of 65 or to have one or more of the conditions that can increase risk. Age and medical risk factors suggest that nearly 40 percent of Americans fall into a higher-risk group. If you want to understand your personal risk better — or make decisions about safety precautions in light of the risk levels of people you'll be spending close time with — there is a National Science Foundation-funded relative-risk calculator app that can help.
What do we know about the rate of long COVID?
Long COVID is real, and it is possible for anyone to get it. That includes kids and vaccinated people — although both are probably less likely to end up with long COVID than unvaccinated adults. Scientists are still figuring out how common long COVID is, but an April 2022 meta-analysis and systematic review of the research that had been peer-reviewed as of July of 2021 found that global average rates could be as high as 43 percent. In addition, there is increased understanding of long-term complications of COVID-19 infection beyond long COVID itself.
Researchers say most studies of long COVID are still frustratingly vague, flawed and hard to compare with one another.
It's still not clear how common long COVID is. Published studies have suggested that long COVID persists at rates anywhere between 4.5 percent and 87 percent. That wild amount of variation has a lot to do with the fact that there is still no universal, set definition of what constitutes long COVID. Self-report surveys have turned up literally hundreds of possible symptoms, and scientists haven't come to an agreement or been able to conclude how to best classify the label. Some of the most clear benchmarks — like a study that showed one-third of COVID patients who were sick enough to be hospitalized were later rehospitalized for other problems at a higher rate than the general population — don't necessarily tell us enough to be extrapolated to the broader demographic of mild COVID patients. A lot of the surveys about long COVID also recruit participants from online communities dedicated to long COVID, which therefore might not do a good job of reflecting the phenomenon's prevalence in the general population. It's messy.
Long COVID is real.
Just because diagnostic criteria are still confusing and there aren't solid numbers on prevalence doesn't mean the syndrome is imaginary. Let's narrow down the symptom list and focus on fatigue as an example. It's a symptom that can cause real, life-changing disability and is a known side effect of other viral infections. Studies find that anywhere between 10 percent and 35 percent of former COVID patients are still experiencing significant fatigue that can't be explained by other illnesses or psychiatric causes six months after their initial infection. Studies have found that long COVID is probably more common in women than in men, in older people than in younger ones and in people who had more symptoms (though not necessarily more severe symptoms) during their initial infection. Another study found some key biological predictors of long COVID: whether the patient had COVID RNA in their blood, which would indicate a higher viral load; whether the patient's blood contained autoantibodies, which attack the body's own tissues are are present in cases of autoimmune disorders, like lupus; whether the person shows signs of reactivation of Epstein-Barr virus, a virus that infects some 90 percent of people in early childhood but usually goes dormant in the body; and whether the patient had Type 2 diabetes before catching COVID. Unfortunately, only diabetes is a predictor you'd likely know about before you get sick with COVID.
Preliminary research suggests long COVID is less likely to occur in vaccinated patients and in patients under age 10.
Vaccination reduces the risk of long COVID by simply reducing the risk of contracting COVID at all, but there is also some recent evidence that breakthrough cases are less likely to develop long-term symptoms. A study of self-reported symptom data from COVID patients in the U.K. found that people who said they were fully vaccinated with two-dose vaccines were about half as likely to still have COVID symptoms 28 days after infection. Likewise, there's a recent study out of the U.K. that found only 4.4 percent of pediatric COVID patients were still experiencing symptoms after 28 days, and less than 2 percent still had symptoms after 56 days. That study fits with a broader context of research that suggests kids can get long COVID but are less likely to do so than adults. However, again, all of this has to be considered through the reality that research on long COVID is messy and that we will learn more from systematic reviews, meta-analyses and growing bodies of evidence over time than from a single study. Early data from studies that haven't yet been peer-reviewed also suggest that getting vaccinated after infection could reduce the risk and severity of long COVID. A recent peer-reviewed, systematic review of long COVID studies in kids and teens also found some encouraging trends. Having had COVID did seem to increase the risk of some long COVID symptoms — but not by huge amounts. We're talking about an 8 percent increase in the risk of loss of smell and a 5 percent increase in the risk of headaches. For most of the other possible long COVID symptoms, however, having had COVID didn't change the likelihood of those symptoms, which means they were not likely a result of long COVID. Prevalence of long COVID symptoms were higher in older teens than in younger children. And better-designed studies found fewer long COVID symptoms at all.
There are long-term side effects of infection besides long COVID.
This can be hard to parse out because there is not a firm definition of what symptoms do and don't constitute long COVID. But if what you have pictured is the months or years of extreme fatigue and brain fog most frequently described in symptom surveys, you should know that there are still ways COVID can harm you long-term — even if you feel like you fully recovered quickly. A study published in February 2022, for example, found that having had COVID — even a mild, transient case — seriously increased the risk of developing cardiovascular problems later. Having contracted and recovered from COVID increased the risk of stroke in the next year by 52 percent, compared with the control group, while the risk of heart failure increased by 72 percent. Researchers found these risks increased significantly even in people who were under the age of 65 and had no other cardiovascular risk conditions.
How can I tell if a new variant surge is happening in my community?
Testing data has gotten less reliable as more people are using at-home rapid COVID-19 tests and fewer cases diagnosed that way are reported to states. At the same time, the CDC has changed their public community-risk map in ways that might not make a local increase in cases clearly apparent to you. However, there are several tools available that can at least give you a better picture of general trends in your area so you can make personal decisions about things like masking or whether it's time to get a booster.
The CDC has multiple ways of tracking COVID rates in communities.
In our section on masking, we talk about the scientific controversy surrounding the CDC's decision to change its basis for masking recommendations from a community-risk map based on the number of cases per country to a new map that combines three metrics: new COVID-related hospital admissions from the previous week, the percentage of hospital beds currently occupied by COVID patients and new COVID cases per 100,000 people over the previous week. This change in methodology had the effect of drastically reducing the number of counties where masks were recommended. But the agency also has other ways that it's tracking the spread of COVID in communities. For example, you can still access maps of community transmission levels, as measured by the agency's old case-based metric, on its Integrated County View page. Just set the data type selection to "Community Transmission". There's also a regular report, created using CDC data and published at the HealthData.gov website, which includes a metric called Rapid Riser Counties. This map shows you which counties meet a series of criteria that suggest COVID transmission is rapidly increasing in that area. Another option is to look at the CDC's National Wastewater Surveillance System maps, which show data and trends from efforts to monitor COVID in sewer water in various counties and cities. All of these maps measure something slightly different, they all have limitations and it is possible for them to show very different pictures of risk for the exact same place. But taken together, they can help you get a better idea of what is happening in your county and whether there's a new variant on the rise where you live.
How likely am I to catch COVID-19 outside?
It is possible to catch COVID outside, even for the vaccinated, but outdoor activities are much lower-risk than indoor ones. Studies have shown that the risks of transmitting COVID outdoors can be extremely low but are affected by factors like air flow, weather and air pollution. Don't assume that 100 people in a tent is an equivalent risk to 100 people spread out in a park.
Studies suggest outdoor interactions are generally much less likely to spread COVID than indoor interactions.
In November 2020, a systematic review found that less than 10 percent of globally documented outbreaks were associated with outdoor settings. The authors of that study have since clarified that this figure was just an estimate — and a high one at that. It was meant to capture the study's upper limits and keep people from getting too complacent while outdoors. The authors wrote in June 2021 that the rate of outdoor transmission is probably much less than 10 percent.
Outdoor transmission can happen, however, and research suggests it is affected by physical, geographic and meteorological circumstances.
There have been cases of outdoor transmission, including a frequently cited case where six out of the 92 people who attended an outdoor tent wedding near Houston in early April 2021 contracted COVID. One of those six died. Vaccination was required for attendance at the wedding, but two people who traveled to Houston from India seem to have brought a breakthrough infection with them. Everyone else who got sick had close contact with them. More contagious variants like delta and omicron affect transmissibility even outdoors. Delta, for instance, is more contagious because it produces higher levels of the virus in nasal passages and lungs, so there's more to spread around when an infected person coughs or sings or talks. And that makes it more likely that someone nearby will get a high-enough dose to catch the disease themselves. But generally speaking, any group activity will be significantly less risky outdoors than the equivalent activity would be if done indoors. There's also more evidence of the ways the physical environment can affect transmissibility outdoors. Much of why COVID is less transmissible outside has to do with air movement — so any circumstance that reduces natural airflow will affect risk, including geographic and meteorological conditions that temporarily reduce airflow in a given region. There is a lot of correlational evidence connecting high particulate matter, such as what happens during forest fires or on low-air-quality days, to COVID spread and severity. Researchers who have modeled airflow think that this might explain the correlations between COVID spread or severity and air pollution. It may not be the pollution itself making COVID worse, but the meteorological conditions that trap polluted air above a city could serve to trap more COVID-contaminated air as well. It's probably wise to think of air-quality alert days also as days where COVID may be more transmissible.
You can reduce the risk of indoor transmission with better ventilation by moving outside air through your space.
Only five states have implemented ventilation standards for preventing COVID transmission in workplaces. But it has been known for years — long before the COVID pandemic — that increasing the movement of air through a building can drastically reduce the risk of contracting airborne pathogens. The amount of reduction varies by the kind of building, how many people are occupying it, and how much ventilation has been added. For example, doubling the airflow in an open-floor-plan office can reduce the relative risk of COVID infection by 44 percent. Most people don't have control over ventilation in their offices, but you can increase ventilation in your home without buying an expensive, new HVAC system. The World Health Organization recommends strategies like opening windows on opposite walls or using an outward-facing fan. When windows are closed, air conditioners and fans can actually end up increasing exposure to the virus by recirculating and mixing indoor air. The WHO recommends opening windows and doors for a few minutes every hour, and changing settings on central AC systems so they're pulling in more outdoor air. Exhaust fans in kitchens and bathrooms are also useful tools to help move air to the outside. Research has also suggested that changing furnace filters regularly and keeping the ducts in your AC or furnace clean can also help. It's also worth noting that in the wake of a federal judge striking down mask mandates on public transportation, airplanes are better ventilated while in flight than most stores and office buildings. There's still risk, for sure, especially in the airport itself or the plane before takeoff and after landing. But a plane's ventilation does help reduce risk, even if you're the only one masking on the flight.
Design and development by Emily Scherer, Julia Wolfe and Elena Mejía. Additional reporting by Anna Rothschild. Story editing by Chadwick Matlin. Copy editing by Andrew Mangan and Curtis Yee.
Have other COVID-19 questions you think we should answer? Email us!


text:
HORSE HEAD THEATRE CO.
HORSE HEAD HOME
HH HISTORY
Red Light Winter
Among the Thugs
Essential Self Defense
Your Family Sucks
Spaghetti Code
The Metal Children
The Jew Who Loves Christmas
THE WHALE (OR...M-D) >
The Project >
!DONATE NOW!
CHAD DEITY
HHH Huzzah!
THE JUDGMENT OF FOOLS >
LIDLESS >
LIDLESS Blog
SENSITIVE GUYS
CHURCH >
SONIC LIFE... >
PETER & THE WOLF
EVOCATION >
WE'RE GONNA DIE >
ADVANCE MAN >
THE FLICK >
WE'RE GONNA DIE Encore >
PETER & THE BEAR
Horse Head Theatre Co. presents the Regional Premiere
The Judgement of Fools
By Bernardo Cubría
Directed by Philip Hays
October 25 - November 12, 2016
@ REC Room, 100 Jackson St., Houston 77002
Director Philip Hays and actor Brendon Duran discuss THE JUDGMENT OF FOOLS on Houston Public Media
ABOUT THE PLAYWRIGHT:
Bernardo Cubría is thrilled to be returning to his hometown! He is a graduate of The University of Houston Theatre program where he and director Philip Hays once vowed to change theatre forever… you're welcome. The Judgment of Fools was originally developed through Inviolet Theatre in NYC. It has has run at INTAR in NYC and at Ammunition Theatre Company in Los Angeles. His play The Redhead Is Coming was part of F*ckfest at The Brick Theatre in NYC and received workshops at The People's Light and Theater in Malvern, PA and at The Fountain Theater in Los Angeles, CA. His latest play Neighbors was part of Crossing Borders at Two River Theatre in New Jersey and has been read at INTAR in NYC and at Ammunition Theatre Company in Los Angeles. He hosts the Theater Podcast: Off and On: A New York Theatre Podcast. He also acts sometimes for that info visit www.bernardocubria.com. Para mi abuelo Ito Tano que sigue contando chistes.
Ronnie Blaine (FOOL 4) is elated to make his Horse Head Theatre Co. debut. Ronnie is a native Houstonian, graduate of The High School for the Performing and Visual Arts (HSPVA) and The University of Houston School of Theatre. He has been performing, writing and directing in Houston for over 20 years. Highlights of his Houston theatre credits include: Full Bloom (Jesse), 1946 (Cpl. Frederick Fox) and Julius Caesar (Artemidorus) at Main Street Theatre; Quills (Asylum Guard/ Lunatic) and The Emperor's New Clothes (The General) at Stages Repertory Theatre; and Tamarie for President (Himself) and The University of Tamarie (The Imperial System) at The Catastrophic Theatre. Ronnie is a proud member of the Screen Actors Guild. His television credits include: J.A.G. (guest), The Suite Life of Zack and Cody (guest), CSI (guest), and CUTS (guest). Currently, Ronnie is a resident director at HITS Theatre in The Heights and theatre instructor at Hogg Middle School.
Jason Duga (FOOL 2) Jason is thrilled to make his Horse Head debut! Houston credits include: Straight White Men (Drew) at Stages Repertory Theatre; Bad Jews (Jonah) with Stages Repertory Theatre and Black Lab Theatre; Oskar and the Big Bully Battle (Oskar) and Oskar and the Curiously Colorful Clash (Oskar) at the Alley Theatre; Gambrels of the Sky (Shadow) at The Landing Theatre Company; and Pollywog (Johnny), Dollface (Perseus), Dracula (Simmons) and Late: A Cowboy Song (Crick) at Mildred's Umbrella. Jason is currently working as a teaching artist for the Alley Theatre's ECE program. Jason has also worked for Swine Palace and Playmakers of Baton Rouge in Louisiana. Memorable credits include A Free Man of Color (Creux/Mercure), How I Became a Pirate (Sharktooth), Pinkalicious (Mr.Pinkerton) and The Wizard of Oz (Scarecrow).
Brendon Duran (THE FOOL) is a Houston native and proud to be making his debut at Horse Head Theatre Co. Theater roles include Teddy Mieras in Ten Ways on a Gun (The Landing Theatre Co.), Bomber Reynolds in Fly (The Ensemble Theater) and Andrew in Beyond Therapy (Vagabond Theater). Brendon is also an improv comedian, performing, teaching and directing regularly with CSz Houston. Improv credits include ComedySportz, (713), Scar in The Lion King: Unscripted, and director of Back to the Future: Unscripted. Brendon is also a founder of Flirt Reynolds, a long-form improv trio that has entertained audiences in Houston (Spring Street Studios, BETA Theater), Denver (Voodoo Comedy Playhouse), Austin (Out of Bounds Comedy Festival, The Hideout Theater), and Los Angeles (Fracas! Improv Festival). He has trained with CSz Worldwide, iO Theater in Chicago, and The Second City Hollywood. Brendon is a graduate of the University of Houston with a BFA in Theatre.
Laura Moreno (FOOL 5) is a recent graduate of the University of Houston BFA Acting Program. Previous credits include: Oklahoma!, The Grapes of Wrath, The History of Tom Jones, Antigone, A Chorus Line, You Can't Take It With You, Agamemnon, Holy Rollers, The Snow Queen, The Best Christmas Pageant Ever, End of Side A, Romeo & Juliet and ¡Bocón!. She was most recently seen as Vera in She Kills Monsters and Kitty in world premiere of Cherry Muffins. Prior to UH, Ms. Moreno spent several years working in the cosmetics and fashion industry in New York City, and is a professional makeup artist. She would like to let everyone know how much she loves her husband, her dog and tacos.
Callina Situka (FOOL 3) is thrilled to be making her Horse Head debut! She has recently been seen as Marianne Angelle in The Revolutionists at Main Street Theater. Other credits include Gambrels of the Sky (Dog) with The Landing Theater, Dollface (Chorus #3) with Mildred's Umbrella, A New Dawn Cabaret (Dawn) with Boiling Point Players, Platanos y Collard Greens (Nilsa) with Ensemble Theater, Give/Take (Milly) with Cone Man Running Productions, Edmonia's Marble (Edmonia Lewis) with Fade to Black, Alley Theater's Houston Young Playwright Exchange, and was a regular actor at Interactive Theater. She holds a B.A. in Theater from the University of Houston.
Cris Skelton (FOOL 6) is excited to make his Horse Head debut. Previous stage credits include: Scapino! (Sylvestro) for Unity Theater; 39 Steps (Clown) for Queensbury Theatre; Rosencrantz and Guildenstern are Dead (Guildenstern) for Obsidian Theater; Cassandra (Apollo) for Mildred's Umbrella; Balm in Gilead (Dopey) for the Back Porch Players; The House of Yes (Anthony) for Tutto Theatre Company. His company memberships have included Rogue Improv in Houston, At-Random in San Marcos, The Coda Project in Austin, The New Movement in Austin and New Orleans; and he was a founding member of Station Theater in Houston. He is also a regular contributor and performer for Grown-Up Storytime and Neo-Benshi for BooTown. He holds a BFA in Acting from Texas State University and trained in improv comedy with The New Movement, iO Chicago, and Upright Citizens Brigade-Los Angeles.
THE CREATIVE TEAM:
Elissa Cuellar (RUN CREW) is ecstatic to be working on her first production with the Horse Head Theatre Company. She is currently working on her BFA in acting at the University of Houston School of Theatre and Dance. Some previous credits include: Our Town, The Prime of Miss Jean Brodie, 33 Variations, The Curious Savage, and The Good Woman of Szechuan.
J. Mitchell Cronin (LIGHTING DESIGN) Main Street Theater: The Revolutionists, RFK: A Portrait of Robert F. Kennedy, Red Hot Patriot, Duck For President, Harriet the Spy, Magic Tree House: A Night in New Orleans, Goodnight Moon, Lilly's Purple Plastic Purse; Prague Shakespeare Company: Venus in Fur, Twelfth Night; Stages Repertory Theatre: Panto Snow Queen: Unfrozen, End of The Rainbow (Assoc. Design), Honky Tonk Angels - Miller Outdoor Theater (Assoc. Design), Mack and Mabel (Asst. Design); Ensemble Theatre: A Soulful Christmas; King Hedley II (Asst. Design); Opera in the Heights: The Telephone, The Medium; DiverseWorks: What Shall We Do Next?; Nicolay Dance Works: Romance, Beyond!, A Wynne Home Nutcracker; Urban Souls Dance Company: Between Two Worlds, Three City Blocks; Technical Director- SHSU Dance: Spectrum: Drift; It's Good to See You Again; Texas Dance Improvisation Festival. Education: Stagecraft Institute of Las Vegas, Sam Houston State University- BFA, Theatre. www.JMCdesigns.info.
Justin Dunford (SCENIC AND PROPERTIES DESIGN, ASSISTANT DIRECTOR) Justin is a local artist, designer, and theatre professional. Dunford graduated from the University of Houston School of Drama with a B.A. in 2005 and has been heavily involved in the local theatre scene. Dunford has performed in many shows and was a company member of Bobbindoctrin Puppet Theatre from 2004 to 2014. He founded Red-handed productions which specializes in Puppet theatre in 2014. He has been involved in the construction and painting of many sets for a variety of theatres and groups in Houston, and has also assistant directed for Classical Theatre on Ubu Roi, Faustus, and The Byrds. This production is Dunford's first with Horse Head Theatre Co. He currently works at The Kinkaid School as a tech theatre assistant.
Elle Eccles (STAGE MANAGER) is a local writer and artist who works in sales and promotions by day and runs to the theatre at night. Elle is honored to be Horse Head's newest company recruit, joining the team as a production fellow. Since joining the theatre scene, Elle has served as a production assistant for the Landing Theatre's reading of La Llorona as part of the New American Voices play reading series and assisted with the Landing Theatre's production of Ten Ways on a Gun as assistant director and board operator.
Philip Hays (DIRECTOR) is an actor, director and theatre educator based out of Houston, TX. He is a company member of Horse Head Theater Co. (winners of the 2016 Houston Press Mastermind Award), for which he co-conceived and performed in the immersive one-man show The Whale; or, Moby-Dick (Best New Play, Houston Press Theater Awards 2016) and acted in 2010's Among the Thugs. He is also a company member of the Classical Theatre Company, where he has directed his own adaptations of The Birds by Aristophanes and Alfred Jarry's Ubu Roi, as well as new adaptations of Christopher Marlowe's Doctor Faustus (by his frequent collaborator Timothy N. Evers), and A Christmas Carol. Last season he directed the regional premiere of Love and Information at Main Street Theater. He has been an Artistic Associate with the Prague Shakespeare Company, where performed in over twelve productions, and directed, co-wrote, and performed in both his original commedia dell'arte-meets-Grand Guignol take on John Webster's The Duchess of Malfi, and the new play The Murder of Gonzago, loosely based on Shakespeare's Hamlet. As an actor on Houston stages he has appeared in numerous roles at the Classical Theatre Company, Main Street Theater, and Houston Shakespeare Festival, as well as appearances with Stark Naked, Mildred's Umbrella, Mosaic Theatre Company and Houston Grand Opera. Philip was a founding member of Houston's alternative theatre collective BooTown. He is a graduate of the University of Houston School of Theatre and Dance and has studied commedia dell'arte with Antonio Fava at the Scuola Internazionale dell'Attore Comico. www.philiphays.com.
Philip was recently named "BEST UTILITY PLAYER" at the 2016 Houston Press Theatre Awards! Congrats, Philip!
Jacey Little (PRODUCTION MANAGER) is the Artistic Director of Horse Head Theatre Co., a freelance theatre director and dramaturg, and Production Manager at the River Oaks Chamber Orchestra (ROCO). Under Jacey's leadership, HH was recognized as a 2016 Houston Press MASTERMIND. Jacey developed and directed Horse Head's The Whale; or, Moby-Dick* by Timothy N. Evers, Philip Hays & Herman Melville (Houston Press 2015 "Best New Play" Winner) and Spaghetti Code* by Abby Koenig (BroadwayWorld Houston 2014 "Best New Play or Musical" Winner). Jacey's recent projects include the development, direction and dramaturgy of Dialogues on Grace* by Cressandra Thibodeaux at 14 Pews, Dollface* by Katharine Sherman with Mildred's Umbrella Theatre Company (Houston Press 2016 "Best New Play," and Ten Ways on a Gun** by Dylan Lamb with The Landing Theatre Company. Jacey is the former Literary Manager and Dramaturg for the Alley Theatre and her Alley dramaturgy credits include Warrior Class* (Kenneth Lin), The Elephant Man, The Mountaintop** (Katori Hall; Arena Stage co-pro), Red, The Seafarer, and What We're Up Against* (Theresa Rebeck). Also at the Alley, she assistant directed and dramaturged The Seagull and Death of a Salesman. As a freelance dramaturg, Jacey has worked with The Landing Theatre Company, Houston Shakespeare Festival, Mildred's Umbrella Theatre Company, Wordsmyth Theatre Company, and Obsidian Art Space. Jacey received her MFA in Dramaturgy and Theatre Historiography from University of Houston and her BFA in Dramaturgy and Acting from University of Oklahoma. *Indicates a world premiere and ** a regional premiere.

redpajama_set_name: RedPajamaCommonCrawl


Create cute and functional storage bins for the little monsters in your life for $1.
Have you figured it out yet that we LOVE Monsters around here? From our Monsters University Party for Statham to our Monsters Inc. Popcorn Balls that we made for Halloween last year; we are a big Sulley and Mike lovin' family. So when I was looking for ways to brighten up the boys' room Monsters was the first thing that came to mind!
Knowing good and well that my little guys would love (with their whole bodies) whatever I bought, or made, I didn't want to spend a lot of money on something that had a good probability of getting ruined. So I went to my go-to place for frugal, crafty supplies; Walmart. I was thinking I would buy some white bins and then paint them blue and green. But I found these super cute bins that were already blue and green AND they were dry erase! The best part…they cost $.98!
Once you have your bins all you need are a few pieces of colored paper and/or card stock, scissors and tape and you're good to go!
Trace circles with your tracers. For Mike you will need a large white circle, medium blue circle and small black circle. For Sulley make 6 medium sized purple circles.
Cut out circles. Since Sulley's spots aren't exact circles I cut jagged purple circles.
Using tape attach circles to bin.
Easy peasy right?! I wanted bins for their dresser so I had a place to store the things we use all the time. That way I wasn't digging through the closet when it was nap time and they were overly tired.
When I was at Walmart I also had to pick up a few other things (because who doesn't when you're at Walmart) and strolled on by the baby section. I saw the cutest Monsters Inc. Crib Bedding Set by Disney Baby. When we were trying to get my oldest to get rid of his pacifier we bribed him with a new big Star Wars toy and it worked. Now we are working on getting my youngest to stay in his crib and not jump out. So I asked him if I got him a new Monsters Inc. blanket if he would stay in his crib. Of course he said yes and you know what? He hasn't jumped out of his crib since! It worked! Does it make me a bad mom that I bribe my kids to do things? No, I don't think so! I love how cute the blanket is and soft the sheet is. On the blanket Sulley is a soft, plush fabric and there has been many a time I have gone in to check on him and and he is cuddled up with Sulley on the blanket.
If Monsters Inc. isn't your kids favorite Disney Baby has so many other cute bedding sets to choose from too including Nemo and Cinderella; and they are super affordable! What is your little one's favorite Disney character?
Oh these are super cute. I have to create some storage options for all the kids. I love how you did this on a super budget because storage boxes are so expensive in the stores.
What a great idea for decorating the storage boxes. I have some plain ones that would look much cuter with a little patterned paper added.
Thanks for linking up your idea at the Bloggers Brags party. I pinned your post to our group board on Pinterest. I can't wait to see what you link up next week!
I would love to see what you create Ali! Thanks so much for hosting!
Love this craft so much! Monsters Inc. was the theme for our second baby, thanks for sharing at Happy Home Life Linky!
Oh fun! My second loves Monsters Inc too! Thanks so much for hosting!
So cute! It ALMOST makes me want another baby 🙂 Well done!
Lol… I love it 🙂 thanks fur stopping by!
This is adorable! What a great project, that doesn't cost a bundle to make. I'll have to show this to my friend who just had a baby!
We love Monsters Inc. These boxes are too cute!
Such a cute idea! My little guy would love this! Thanks!
Thanks so much Michelle! They do make it much easier to reach things. And I LOVE the new bedding…thank you!!
How adorable, my daughter loves monsters!
These are adorable! Your family is obsessed with Monster, Inc. and mine is obsessed with Minne Mouse! I love finding ways to incorporate Minne decor into her room! Your Monster, Inc. room is adorable!
Thank you Ruthie! And yes they totally are… It's always fun to find things for kids like and incorporate them into everyday life.
This was such a cute idea! This would look great idea when hosting a party. Love it!
They totally would! Thanks Jessica!
Thanks Tara! I'm a little OCD when it comes to having a place for everything…hopefully some if rubs off on my boys 🙂 Thanks so much for hosting Tara we'll see you next week!


Rare find! Over 10 acres off Hwy 18 near Central. Currently zoned A-20. Property is fenced and level. Easy access off 300 South or hwy 18. Rezone for a mini ranch home-site or one of the many commercial opportunities. 2.01 Acre feet of water included. Water right 81-4471.


text:
Careers » Career Path » Do I have what it takes to work in international aid & development?
Do I have what it takes to work in international aid & development?
"I just want to make the world a better place."
Sure, who doesn't? Let's cut to the chase; you are going to need a lot more than enthusiasm and the desire to make people happy if you want to work in international aid and development. This is an especially tough area of work to break into and there is a lot of competition for positions.
You need to be decisive and effective. You are going to be spending huge sums of other people's money on important projects and there will rarely be the option of running over budget or getting extra personnel on board. You are likely to be over worked and underpaid, safe in the knowledge that there are hundreds of others willing to take your place.
What options do I have within this field?
International aid and development is one of the most important areas of work in the world. Without the hard work and dedication of the people that work in this field, millions of people across the world would suffer.
If you consider the fantastic work done by international aid workers in response to the Haiti earthquake disaster and the devastating floods in India, the importance of this work becomes even more apparent.
However, the career options in this area may be less obvious. Let's take water engineers or web developers as a couple of roles that may not immediately come to mind.
Of course, many health professionals, teachers, fundraisers and administrators get involved, but there are an increasing number of economists, sociologists, psychologists and other professionals immersed in the exciting world of international aid and development.
Your options are incredibly broad. You may find yourself working in the UK or abroad. You may be working on a short term project or focusing on a lifelong aim. Your work could focus on building wells, implementing education strategies or organising the logistics of moving hundreds of tonnes of food supplies to a disaster zone.
What subsectors can I work in?
Although there's a lot going on, international aid and development work can be broadly divided between the following areas of work:
Planning.
All of these specialist career paths can be undertaken in the UK or abroad.
Reporting is an important part of international aid and development, which has the dual role of quantifying the issues that exist and measuring the performance of projects that have finished or are currently underway. This often involves people working out in the field, meeting people, asking questions and collecting data.
The information gathered in reports is great for planning future budgets and projects. Once the issues are clear, action can be taken, plans can be drawn up and money can be allocated. The same information also serves as the basis of advocacy.
Advocacy and lobbying are incredibly important aspects of international aid and development. This process is used to persuade companies and governments to support, condemn or review certain issues, situations and projects.
From time to time, new projects are considered necessary. These can have short, medium or long term goals. For example, the Millennium Development Goals are long term objectives, whilst a short term goal may be in the immediate aftermath of a natural disaster.
New projects need to be planned and resourced with contingencies made for the many contributing factors that make international aid and development such an interesting and stimulating subsector.
Often, you will be working with fewer resources than you would hope for, to tight schedules and in a constantly changing landscape. Consequently, a career in international aid and development can be highly frustrating and, at times, disheartening. At the same time, this is a great field to pursue if you're energetic, positive and up for a challenge.
Check out the occupational profile of an international aid/development worker to find out more!
Who handles foreign affairs & international…
What does human rights work involve?
What industries need research & development scientists?
What is public finance?
What is sports development?
Sustainable Development & Regeneration - What is…
What is a career in tax like?
What's SEN teaching about?
Why get into maritime transport?
How to become a Psychologist
Why get into particle physics?
Why do we need to research and engineer prototypes?
1 What options do I have within this field?
2 What subsectors can I work in?


Leadership & Staff - First Congregational United Church of Christ, Washington D.C.
On Sunday, March 24, at a special meeting, the congregation agreed to contract with the Rev. Michael Durst to be our interim minister. Mike was raised in a Jewish household, and came to Christianity through his marriage to Carol Emig. He spent a number of years worshiping in an Episcopal Church before finding his home in the UCC. He's currently a member of Pilgrim UCC.
Mike's first career was as a tax lawyer. A significant part of his practice in recent years has been helping the world's poorer countries raise revenue by more effectively taxing multi-national businesses. As part of this work, he has traveled extensively internationally, seeing first hand and responding to the effects of colonialism and racism around the world. He attended seminary part-time while working full-time as a lawyer. He received his Master of Divinity degree from Wesley Theological Seminary in 2012. He completed his Clinical Pastoral Education at Goodwin House in Northern Virginia. Mike has served Pilgrim UCC in Wheaton as both the Interim Minister and the Associate Minister of Christian Education and Experience.
Sam is grateful to serve alongside the First Church community as Minister of Faith Formation. He feels called to create a space to help all ages, from infants to adults, sense God's presence in their lives. Sam desires to make the church more about how we relate to God and with one another than a static adherence to tradition, creed, or even our history. He believes God is still speaking, and through Sunday school, service, story sharing and song, prayer and acts of solidarity with the marginalized, that we are provided opportunities to hear God's call and act upon it. Sam is ordained in the Presbyterian Church (PCUSA) and a graduate of Union Presbyterian Seminary, the University of Kansas, and Haverford College. He is joined by his wife, Lauren, and their two sons, Brendan and Ryan. Sam loves the Nationals, playing baseball, and living in DC!
Byron devotes his church hours to building relationships with a variety of organizations in the Greater Washington region (including Ford's Theater, Washington Bach Consort, National Symphony Orchestra, Choral Arts Society) who use the church's space for concerts, lectures, forums, classes, and more. His service on the Site Development Design Team and a career in direct and brand marketing gives him a unique perspective on how the building can be used and promoted to build the wider community in the heart of the city. He is a graduate of Georgetown University and participated in immersion language training in Chiapas, Mexico.
Cindy joined the staff of First Congregational UCC in March of 2015. After having lived in the DC area in her youth, she moved back to the area from Connecticut to be closer to family. Cindy earned her Bachelor's Degree in Music Education from the University of Maryland. She served as the administrative assistant at two churches in Connecticut, along with holding several positions in the legal field and teaching private piano lessons for over 25 years. Cindy is happy to be a part of the staff at First Church. Please stop by the office and say hello!
Kim joined as First Congregational in 1993 as a young adult and is now raising her three children in the church. She values the relationships that she has with members of the congregation, and the support they have provided as she's moved through the various stages of her life. She works as an economist for a small business in Virginia and is working on perfecting her baking skills.


A five-time winner since chasing home Lord Scoundrel and Alelchi Inois, also trained by Mullins, in the Plate a year ago, Ballycasey last saw action when scoring at Killarney in May.
That run gives Alelchi Inois a clear edge over stablemate Devils Bride, while it also makes him a credible threat to the selection.
Earlier in the week, Thursday's Clonmel Oil Chase was won in very fortunate style by Alelchi Inois, and the only reaction from the handicapper was to raise Outlander 4lb to 157 for his lastfence fall with the race at his mercy.
THE Willie Mullinstrained Alelchi Inois was gifted yesterday's Grade 2 Clonmel Oil Chase by the last fence fall of former stablecompanion Outlander.
Not only did he keep the partnership intact, he then pulled the Grade 2 race out of the fire by giving the 9/1 chance a strong drive to get back up for a half-length win over Alechi Inois.
Upgrading of SS between INOIS - DAFLEIAS among DOMOKOU - LARISSA, namely the replacement of existing switches with joints soldered with new changes on concrete sleepers or on wood.
Clonmel Brian Sheerin WILLIE MULLINS admitted that Alelchi Inois needed a heavy slice of luck when scoring in the feature Clonmel Oil Chase, but both Westerner Lady and Miss Me Now went on to grind out wins on merit, bringing up a treble for the master of Closutton.
Although unable to trouble Sub Lieutenant in his comeback, Outlander will strip fitter today and gets the vote to beat Alelchi Inois.
He has plenty to fear from the prolific and undefeated chaser Alelchi Inois, while Chancol looked good when scoring here last month.
Gordon Elliott's Outlander, trained last season by Mullins, looked a likely winner approaching the last fence when holding a three-length advantage over a ridden-along Alelchi Inois, but the leader failed to take off properly and ploughed through the birch in the hands of Bryan Cooper.
from his main rivals, although having his first run since chasing home Alelchi Inois in a chase at Punchestown on June 1.
He had a lovely run over a bit shorter at Punchestown back in June when second to Alelchi Inois and he likes the track.


text:
Taming of a shape-shifter molecule
Isomer convergence of a permanently fluctuating coordination cage
Shape-shifter molecules are in never-ending motion. Their structure fluctuates because the carbon bonds that hold them together constantly break up and form again. Researchers have now found a way to "tame" a shape-shifter molecule called bullvalene. In the journal Angewandte Chemie, they report that integrating the molecule into a coordination cage enables its shape-shifting behavior to be restricted through molecular recognition. Such form capturing could play a role in responsive materials.
Chemical bonds between carbon atoms can be strong, as in the hydrocarbon gas ethane, or strained, as in triangular cyclopropane, or they can fluctuate between both kinds, such as in the organic hydrocarbon compound bullvalene.
This molecule, discovered around 1960, fascinates chemists because its structure is in constant motion. Its outer shape remains the same, but the bonds between the carbon atoms continually change. This prevents the molecule from performing reactions that lead to defined substances. What is a nightmare for some chemists, others see as an opportunity because bond fluctuation also means that the molecule can react very quickly to external stimuli. Chemists envision that fluctuating molecular systems could participate in functional molecular switches or other responsive systems.
A team led by organic chemist Thomas Fallon and Witold Bloch of the University of Adelaide, Australia, have now been able to "tame" the fluctuating bullvalene molecule by integrating it into a self-assembling coordination cage. To make the cage, the researchers attached two metal-binding residues to the bullvalene molecule. When they added a metal salt, they found that coordination of these residues to the metal ions led to the self-assembly of the molecules to form a mixture of shape-shifting coordination cages.
"The key to the restriction of bullvalene's fluctional motion was the use of negative ions such as chloride or iodide," Fallon explains. "When these ions were added into the cage mixture, a significant convergence from over 200,000 possible isomers to only one dominating cage form occurred." As a driving force, the team identified molecular recognition, which is a term used to describe specific interactions between molecules and ions. This specific interaction led to the formation of a dominating cage isomer where four bullvalenes, held together on the top and bottom by metal ions, were arranged around the negative ion like curved struts of a basket.
Thus, cage formation brought the previously uncatchable bullvalene molecule to a certain degree of rest. The authors found that only one conversion route between isomers remained, always leading to the dominating form. They anticipate that their bullvalene taming could help in the development of molecular systems where fast adaptation to external stimuli is required.
(2949 characters)
Dr. Thomas Fallon and Dr. Witold Bloch lead research groups at the University of Adelaide, Australia. They focus on organic synthesis of, for example, shape-shifting molecules and the supramolecular materials chemistry of structures such as metal–organic cages, respectively.
10.1002/anie.202115468
Guest-Dependent Isomer Convergence of a Permanently Fluxional Coordination Cage
Mario Mueller
mmueller@wiley.com
Office: 49-620-160-6571
Australian Research Council, Marsden Fund
/Physical sciences/Chemistry/Molecular chemistry/Molecules/Molecular structure
/Physical sciences/Chemistry/Molecular chemistry/Ions/Anions
/Physical sciences/Chemistry/Supramolecular chemistry/Molecular recognition
/Physical sciences/Chemistry/Organic chemistry/Stereochemistry/Isomers
https://onlinelibrary.wiley.com/page/journal/15213773/homepage/press/202140press.html


I will not send you money, you must not have kids!
Well I am college graduate. I am working in my human resource management field working hard to advance in my career. I love to have fun and enjoy life. If you want to know more message me.
hola mi nombre es miguel tengo 21ano soy de puertorriqueno y bueno megusta mucho viajar megusta la playa el jangueo el cine y megusta hacer muchos amigos/a .
nd see others having fun.Likesto go too movies,romantic diner,concerts,spend time with family and friends.


After 13,000 miles and 17 months at sea, Irishman Enda O'Coineen passed through the finishing line of the Vendee Globe course to mark the end of his solo sailing lap of the planet.
On 6 November 2016 O'Coineen crossed the starting line of the solo non-stop race around the world From France to France. His world came crashing down around him on New Years Day 2017 when he broke his mast 180 miles south of New Zealand in one of the most remote parts of the planet.
Undeterred, the Irish team joined forces with a French entrant that was also forced to head to New Zealand for essential repairs. The new Team, Le Souffle du Nord Kilcullen Team Ireland emerged from a boat shed in Christchurch with a newly repaired and jointly branded yacht to complete the voyage.
The second half of this epic adventure began on 26th January 2018 when O'Coineen sailed away alone from New Zealand with a destination some 13,000 miles away, through the Pacific Ocean, around Cape Horn, and back up the Atlantic and into Les Sables d'Olonne. This leg took 66 days alone at sea of nonstop sailing.
The voyage saw him tackle ginormous seas off Cape Horn, becalmed waters along the coast of South America, and the last of the wild winter storms in the north Atlantic.
By completing the solo lap of the planet Enda enters the history books of Irish sailing. Still to this day, 50 years since Sir Robin Knox-Johnston first sailed alone non-stop around the planet no Irish person has achieved this and only a handful have lapped the planet alone with just one stop.